Skip Navigation


NDT Advance Access originally published online on September 27, 2005
Nephrology Dialysis Transplantation 2005 20(12):2601-2604; doi:10.1093/ndt/gfi155
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/12/2601    most recent
gfi155v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Navarro, J. F.
Right arrow Articles by Mora, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navarro, J. F.
Right arrow Articles by Mora, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Role of inflammation in diabetic complications

Juan F. Navarro1,2,3 and Carmen Mora2,3

1 Servicio de Nefrología, 2 Instituto Canario de Investigación Biomédica, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife and 3 Centro de Investigaciones Biológicas, CSIC, Madrid, Spain

Correspondence and offprint requests to: J. F. Navarro, Servicio de Nefrologia, Hospital Nvestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain. Email: jnavgon@gobiernodecanarias.org

Keywords: cytokines; diabetes; diabetic nephropathy; inflammation; pentoxifylline; tumor necrosis factor-{alpha}

The first 150 words of the full text of this article appear below.



   Introduction
 
Diabetes mellitus, especially type 2 diabetes, is a public health problem which has reached epidemic proportions due to the rapidly increasing rates of this disease worldwide. Target organ complications, secondary to diabetes, will be one of the most important medical concerns of the coming decades. A clear example is diabetic nephropathy (DN), which has become the single most frequent cause of end-stage renal disease, in other words: ‘a medical catastrophe of worldwide dimensions’ [1].

In the last few years, our knowledge of DN and its clinical course, the factors that influence it as well as the progression of renal injury and the possibilities of effective therapeutic approaches have substantially improved. From a pathophysiological point of view, the critical importance of metabolic and haemodynamic factors for the risk of developing DN is clear. However, the intimate mechanisms leading from chronic hyperglycaemia to the development of renal injury are complex . . . [Full Text of this Article]



   Diabetes mellitus: an evolving disease. From a metabolic disorder to an inflammatory condition
 


   Inflammation and diabetic complications
 


   Diabetic nephropathy: a matter of inflammation
 


   Tumor necrosis factor-{alpha}: an old actor in a new scenario
 


   Treatment of diabetic nephropathy: new perspectives, new targets
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
L. J. He, M. Liang, F. F. Hou, Z. J. Guo, D. Xie, and X. Zhang
Ethanol extraction of Picrorhiza scrophulariiflora prevents renal injury in experimental diabetes via anti-inflammation action
J. Endocrinol., March 1, 2009; 200(3): 347 - 355.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. A. Niewczas, L. H. Ficociello, A. C. Johnson, W. Walker, E. T. Rosolowsky, B. Roshan, J. H. Warram, and A. S. Krolewski
Serum Concentrations of Markers of TNF{alpha} and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes
Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 62 - 70.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. F. Navarro-Gonzalez and C. Mora-Fernandez
The Role of Inflammatory Cytokines in Diabetic Nephropathy
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 433 - 442.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. J. Friedman, H. G. Rennke, E. Csizmadia, K. Enjyoji, and S. C. Robson
The Vascular Ectonucleotidase ENTPD1 Is a Novel Renoprotective Factor in Diabetic Nephropathy
Diabetes, September 1, 2007; 56(9): 2371 - 2379.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. T. Lindenmeyer, M. Kretzler, A. Boucherot, S. Berra, Y. Yasuda, A. Henger, F. Eichinger, S. Gaiser, H. Schmid, M. P. Rastaldi, et al.
Interstitial Vascular Rarefaction and Reduced VEGF-A Expression in Human Diabetic Nephropathy
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1765 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Schmid, A. Boucherot, Y. Yasuda, A. Henger, B. Brunner, F. Eichinger, A. Nitsche, E. Kiss, M. Bleich, H.-J. Grone, et al.
Modular Activation of Nuclear Factor-{kappa}B Transcriptional Programs in Human Diabetic Nephropathy
Diabetes, November 1, 2006; 55(11): 2993 - 3003.
[Abstract] [Full Text] [PDF]